An observational study reported an 8.5% temporary interruption of the Proprotein Convertase Subtilisin/Kexin type 9 (PCSK-9) therapy for a mean period of 65 ± 1.5 days in patients with dyslipidemias treated with PCSK9 inhibitors (PCSK9i) who missed the cardiologic follow-up visit during the first lockdown. Here, PCSK9 is linked to metabolic syndrome.